Published in Cancer Weekly, February 8th, 2005
EBV "is present within the tumor cells of most cases" of NPC," pathologists in the United States explained. "Recent studies suggest that tumor burden is proportional to the level of EBV DNA in blood and that rapid blood testing can be used to guide therapeutic intervention."
However, the "relative utility of viral load vs. serology has been insufficiently studied," argued H.X. Fan and colleagues at the University of North Carolina. In their study, "EBV viral load was measured by quantitative PCR using either real-time or end-point detection...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.